{
    "clinical_study": {
        "@rank": "148152", 
        "acronym": "TEAL", 
        "arm_group": [
            {
                "arm_group_label": "TDM1 with Laptinib followed by Abraxane", 
                "arm_group_type": "Experimental", 
                "description": "Trastuzumab Emtansine IV every three weeks plus Lapatinib oral daily for a total of six (6) weeks followed by Abraxane IV weekly for twelve (12) weeks."
            }, 
            {
                "arm_group_label": "Herceptin plus Lapatinib followed by paclitaxel", 
                "arm_group_type": "Active Comparator", 
                "description": "Trastuzumab (Herceptin) IV weekly plus Lapatinib oral daily for a total of six (6) weeks, followed by weekly IV paclitaxel for twelve (12) weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "Purpose: The purpose of this study is to evaluate the Pathological Complete Response (pCR)\n      of the breast when trastuzumab emtansine (TDM-1) plus Lapatinib plus Abraxane is combined in\n      newly diagnosed HER2 positive breast cancer.\n\n      This is a randomized, open label Phase II neo-adjuvant study comparing the efficacy of\n      neoadjuvant Trastuzumab Emtansine (TDM1) plus lapatinib follow by Abraxane, versus\n      trastuzumab (herceptin) plus Lapatinib follow by paclitaxel."
        }, 
        "brief_title": "Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab With Lapatinib and Paclitaxel", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Female gender;\n\n          -  Age \u226518 years;\n\n          -  Performance Status- Eastern Cooperative Oncology Group (ECOG) 0-1\n\n          -  Histologically confirmed invasive breast cancer:\n\n          -  Primary tumor greater than 1 cm diameter, measured by clinical examination and\n             mammography or ultrasound.\n\n          -  Any N,\n\n          -  No evidence of metastasis (M0) (isolated supra-clavicular node involvement allowed);\n\n          -  Over expression and/or amplification of HER2 in the invasive component of the primary\n             tumor and confirmed by a certified laboratory prior to randomization.\n\n          -  Known hormone receptor status.\n\n          -  Hematopoietic status:\n\n          -  CBC not less than .75 of institutional lower limit. Absolute neutrophil count \u2265 1,5 x\n             10^9/L, Platelet count \u2265 100 x 10^9/L, Hemoglobin at least 9 g/dl,\n\n          -  Hepatic status:\n\n        Serum total bilirubin \u2264 2 x upper limit of normal (ULN). In the case of known Gilbert's\n        syndrome, a higher serum total bilirubin (< 1.5 x ULN) is allowed, Aspartate\n        Aminotransferase (AST) and Alanine Aminotransferase (ALT) \u2264 3.5 times ULN, Alkaline\n        phosphatase \u2264 2.5 times ULN, \u2022 Renal status: Creatinine \u2264 1.5mg/dL,\n\n        \u2022 Cardiovascular: Baseline left ventricular ejection fraction (LVEF) \u00b3 \u226550% measured by\n        echocardiography (ECHO) or Multiple Gate Acquisition (MUGA) scan,\n\n          -  Negative serum or urine \u03b2-hCG pregnancy test at screening for patients of\n             childbearing potential within 2-weeks (preferably 7 days) prior to randomization.\n\n          -  Fertile patients must use effective contraception (barrier method - condoms,\n             diaphragm - also in conjunction with spermicidal jelly, or total abstinence. Oral,\n             injectable, or implant hormonal contraceptives are not allowed)\n\n          -  Signed informed consent form (ICF)\n\n          -  Patient accepts to make available tumor samples for submission to central laboratory\n             to conduct translational studies as part of this protocol.\n\n        Exclusion Criteria:\n\n          -  Previous (less than 5 years) or current history of malignant neoplasms, except for\n             curatively treated: Basal and squamous cell carcinoma of the skin; Carcinoma in situ\n             of the cervix.\n\n          -  Patients with a prior malignancy diagnosed more than 5 years prior to randomization\n             may enter the study.\n\n          -  Preexisting peripheral neuropathy \u2265 grade 2\n\n          -  Known history of uncontrolled or symptomatic angina, clinically significant\n             arrhythmias, congestive heart failure, transmural myocardial infarction, uncontrolled\n             hypertension (\u2265180/110), unstable diabetes mellitus, dyspnea at rest, or chronic\n             therapy with oxygen;\n\n          -  Concurrent disease or condition that would make the subject inappropriate for study\n             participation or any serious medical disorder that would interfere with the subject's\n             safety;\n\n          -  Unresolved or unstable, serious adverse events from prior administration of another\n             investigational drug;\n\n          -  Dementia, altered mental status, or any psychiatric condition that would prevent the\n             understanding or rendering of ICF;\n\n          -  Malabsorption syndrome, disease significantly affecting gastrointestinal function, or\n             resection of the stomach or small bowel. Subjects with ulcerative colitis are also\n             excluded;\n\n          -  Concurrent neoadjuvant cancer therapy (chemotherapy, radiation therapy,\n             immunotherapy, biologic therapy other than the trial therapies);\n\n          -  Concurrent treatment with an investigational agent or participation in another\n             therapeutic clinical trial;\n\n          -  Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs\n             chemically related to trastuzumab Emtansine, trastuzumab, lapatinib, paclitaxel,\n             abraxane or their components;\n\n          -  Pregnant or lactating women;\n\n          -  Concomitant use of CYP3A4 inhibitors or inducers\n\n          -  Other concurrent severe and/or uncontrolled concomitant medical conditions (e.g.\n             active or uncontrolled infection, uncontrolled diabetes) that could cause\n             unacceptable safety risks or compromise compliance with the protocol\n\n          -  Patients have an active infection and require IV or oral antibiotics.\n\n          -  Pregnant or breast-feeding women\n\n          -  Patients unwilling or unable to comply with the protocol"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 18, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02073487", 
            "org_study_id": "1013-0164"
        }, 
        "intervention": [
            {
                "arm_group_label": "TDM1 with Laptinib followed by Abraxane", 
                "description": "trastuzumab emtansine [Kadcyla] Intravenous repeating dose every 3 weeks", 
                "intervention_name": "Trastuzumab Emtansine", 
                "intervention_type": "Drug", 
                "other_name": [
                    "TDM1", 
                    "Kadcyla"
                ]
            }, 
            {
                "arm_group_label": "Herceptin plus Lapatinib followed by paclitaxel", 
                "description": "Trastuzumab (Herceptin) Intravenous repeating dose weekly", 
                "intervention_name": "Trastuzumab", 
                "intervention_type": "Drug", 
                "other_name": "Herceptin"
            }, 
            {
                "arm_group_label": [
                    "TDM1 with Laptinib followed by Abraxane", 
                    "Herceptin plus Lapatinib followed by paclitaxel"
                ], 
                "description": "Lapatinib repeating dose taken orally every day for 6 weeks", 
                "intervention_name": "Lapatinib", 
                "intervention_type": "Drug", 
                "other_name": "tykerb"
            }, 
            {
                "arm_group_label": "TDM1 with Laptinib followed by Abraxane", 
                "description": "Abraxane repeating dose weekly IV for up to 12 weeks", 
                "intervention_name": "Abraxane", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Herceptin plus Lapatinib followed by paclitaxel", 
                "description": "Paclitaxel IV repeating dose weekly for up to 12 weeks", 
                "intervention_name": "Paclitaxel", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Paclitaxel", 
                "Maytansine", 
                "Trastuzumab", 
                "Lapatinib"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Neoadjuvant Breast Cancer", 
            "HER2 positive Breast Cancer"
        ], 
        "lastchanged_date": "February 25, 2014", 
        "link": {
            "url": "http://www.houstonmethodist.org/clinicaltrials"
        }, 
        "location": {
            "contact": {
                "email": "ccresearch@houstonmethodist.org", 
                "last_name": "Houston Methodist Cancer Center", 
                "phone": "713-441-0629"
            }, 
            "facility": {
                "address": {
                    "city": "Houston", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "77030"
                }, 
                "name": "Houston Methodist Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Angel A Rodriguez, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Daniel Lehane, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Tejal Patel, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Monisha Singh, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Jorge Darcourt, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized Open Label Phase II Trial Of Neoadjuvant Trastuzumab Emtansine (Te) In Combination With Lapatinib (L) Follow by Abraxane (A) Compared With Trastuzumab Plus Lapatinib Follow by Paclitaxel In Her 2 Neu Over-Expressed Breast Cancer Patients (TEAL Trial)", 
        "other_outcome": {
            "description": "To determine predictive markers for sensitivity and resistance to Trastuzumab Emtansine when combined with Lapatinib follow by Abraxane", 
            "measure": "determine predictive markers", 
            "safety_issue": "No", 
            "time_frame": "approximately 1 year"
        }, 
        "overall_contact": {
            "email": "ccresearch@houstonmethodist.org", 
            "last_name": "Houston Methodist Cancer Center", 
            "phone": "713-441-0629"
        }, 
        "overall_official": {
            "affiliation": "The Methodist Hospital System", 
            "last_name": "Jenny CN Chang, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Federal Government", 
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To evaluate the pathological complete response rate (pCR) in the breast after treatment with Trastuzumab Emtansine plus Lapatinib follow by Abraxane in women with HER2 Neu over-expressed breast cancer patients.", 
            "measure": "pathological complete response rate (pCR)", 
            "safety_issue": "Yes", 
            "time_frame": "From date of randomization until the date of surgery, approximately 16 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02073487"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To determine the clinical response rate in patients with palpable disease.", 
                "measure": "Clinical Response Rate", 
                "safety_issue": "No", 
                "time_frame": "From date of randomization until completion of neoadjuvant treatment, approximately 16 weeks"
            }, 
            {
                "description": "To determine the imaging response to neoadjuvant therapy through breast imaging (mammogram, ultrasound and MRI) using RECIST.", 
                "measure": "breast imaging response to treatment", 
                "safety_issue": "No", 
                "time_frame": "approximately 16 weeks"
            }, 
            {
                "description": "To compare overall objective response rate in both treatment groups.", 
                "measure": "objective response rate", 
                "safety_issue": "No", 
                "time_frame": "approximately 16 weeks"
            }, 
            {
                "description": "To assess toxicity, safety and efficacy of Trastuzumab Emtansine when combine with Lapatinib follow by Abraxane", 
                "measure": "toxicity, safety and efficacy of study treatment", 
                "safety_issue": "Yes", 
                "time_frame": "approximately 16 weeks from randomization"
            }
        ], 
        "source": "The Methodist Hospital System", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Celgene Corporation", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "GlaxoSmithKline", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "The Methodist Hospital System", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}